Skip to content

Cochrane Database of Systematic Reviews

ISSN 1464-780X

6 papers in the library · 422 citations · publishing 2010-2024

Papers

Sort Most recent Most cited

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases

Cochrane Database of Systematic Reviews September 11, 2024 Sivan Schipper, Kabir Nigam, Yasmin Schmid et al. 34 citations

Implications for practice Psychedelic-assisted therapy with classical psychedelics (psilocybin, LSD) may be effective for treating anxiety, depression, and possibly existential distress, in people facing a life-threatening disease. Psychedelic-assisted therapy seemed to be well tolerated, with no treatment-emergent serious adverse events reported in the studies included in this review. However,...

Psychedelic/entactogen-assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care

Cochrane Database of Systematic Reviews November 21, 2022 Sivan Schipper, Kabir Nigam, Vanessa Piechotta et al. 4 citations

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of psychedelic/entactogen‐assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in adult palliative care.

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.

Cochrane Database of Systematic Reviews October 8, 2021 Rebecca L. Dean, Tahnee Marquardt, Claudia C. Hurducas et al. 41 citations

BACKGROUND Glutamergic system dysfunction has been implicated in the pathophysiology of bipolar depression. This is an update of the 2015 Cochrane Review for the use of glutamate receptor modulators for depression in bipolar disorder. OBJECTIVES 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar...

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.

Cochrane Database of Systematic Reviews September 12, 2021 Rebecca L. Dean, Claudia C. Hurducas, Keith Hawton et al. 97 citations

BACKGROUND Many studies have recently been conducted to assess the antidepressant efficacy of glutamate modification in mood disorders. This is an update of a review first published in 2015 focusing on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor...

Ketamine as an adjuvant to opioids for cancer pain

Cochrane Database of Systematic Reviews June 28, 2017 Rae Frances Bell, Christopher Eccleston, Eija Kalso 246 citations

BACKGROUND: This is an update of a review first published in 2003 and updated in 2012.Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of refractory cancer pain, when opioids alone or in combination with appropriate adjuvant analgesics prove to be ineffective. Ketamine is known to have psychomimetic (including...

Mindfulness-based ‘third wave’ cognitive and behavioural therapies versus treatment as usual for depression

Cochrane Database of Systematic Reviews September 8, 2010 R. Churchill, T. Moore, P. Davies et al.

This is the protocol for a review and there is no abstract. The objectives are as follows: To examine the effectiveness and acceptability of all third wave CBT approaches compared with treatment as usual/waiting list/attention placebo control conditions for acute depression. To examine the effectiveness and acceptability of different third wave CBT approaches (ACT, compassionate mind training,...